Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460811
Status:
COMPLETED
Last Update Posted:
2013-02-04
First Post:
2007-04-13
Brief Title:
Randomized Double-blind Dose-range-finding Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation IBS-C
Sponsor:
Ironwood Pharmaceuticals Inc
Organization:
Ironwood Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Multicenter Double-blind Placebo-controlled Dose-range-finding Parallel-design Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Irritable Bowel Syndrome With Constipation
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety efficacy and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None